• Head of Business Development (Out-licensing) for North America with an added responsibility for global business development of specialty and branded products i.e. Biosimilars with a strong focus on regulated markets i.e. US, Europe, MENA. • Responsible for handling Indian pharma MNCs; operational globally to centralize deals. • Overlooking global portfolio selection, business continuity and strategy for Generics, 505(b)2, Value Added Medicines, Fixed-dose combinations, Rare/Orphan Drugs, Novel Modalities, Specialty Brands and Biosimilars for global markets.

• Arphio is a young member of Aztiq group with a focus to become an end-to-end integrated Rare Disease company. • Responsible for Out-Licensing of Novel rare diseases assets to Ex-US markets i.e. LATAM, MENA and APAC to provide un-met medical needs to patients suffering from rare diseases. • Focused on In-licensing, finding co-development opportunities, M&A opportunities, JVs to help Arphio’s exponential growth.

• Head of Business Development (Out-licensing) for North America with an added responsibility for global business development of specialty products with a strong focus on regulated markets. • Also, overlooking global portfolio selection, business continuity and strategy for Generics, 505(b)2, Value Added Medicines, Fixed-dose combinations, Rare/Orphan Drugs, Novel Modalities, Specialty Brands and Biosimilars. • Responsible for In-licensing, co-development, M&As, JVs as part of strategic partnerships. • Working with a broad portfolio of Biosimilars, Branded Generics, Innovative, Rare Diseases, Orphan and Niche drugs, ANDA’s, 505(b)2, Differentiated Products and Value-Added Medicines. • Added commercial B2C responsibility i.e. to head direct to market strategy for a few added value drugs to launch them in Europe and US markets.

• Global business development role with a focus on regulated markets i.e. US, EU and Japan. • Signed multi-Million-dollar deals for late-stage Biosimilar assets for US and EU markets. • Out-licensing of Alvotech’s biosimilar assets from near-term submissions i.e. late stage ready to file and early-stage assets with a horizon to file within the next 5-7 years. • In-licensing as well as finding co-development opportunities, M&As to build the next wave of biosimilar assets for Alvotech.

• Head of Business development function (Global) - deal signed for a multi-million $ global rights of biosimilars and vaccines assets. • In- and & out- licensing of biosimilars, novel biologics for CuraTeQ Biologics, Vaccines for Auro Vaccines, and Synthetic Peptide API sales for Auro Peptides – subsidiaries of Aurobindo Pharma Ltd. (2nd largest company in India by revenues, presence in 155 countries). • Handling a portfolio of - o 15+ biosimilars assets being developed for regulated markets i.e., for US and EU. o 4+ vaccine assets being developed for regulated markets, GAVI eligible counties (WHO-QP) and India. o 10+ synthetic peptides API sales, CEP and DMF’s filed.

• Signed 15 + deals amounting 120 million+ USD (Cumulative) in revenue - out-licensing of Biosimilars (multi-product deals), long term API/DS supply agreements, P2P agreements, CDMO/CMO (NBE’s and biosimilars) deals, in India, Brazil, South Korea, LATAM, Russia, Turkey, Pan-Europe, Australia and USA. Finalised out-licensing deals with binding termsheet closed to signing in MENA, Japan and other APAC markets for various biosimilar molecules. • Launched 3 Biosimilars in India - full life-cycle management from development, clinical trials, regulatory approvals, licensing deals, supply chain management and launch. • Pioneered the key account management with marketing and business teams of all the current partners. • First to launch on LOE market access strategy through portfolio selection/prioritization, regulatory landscape analysis and competitive intelligence. • Extensively involved Private Equity discussions to bring further funds to expand business and footprint in India and USA. • Also heading the project management function with 26+ (in-house and client projects) with 3 biosimilar approvals, 4 biosimilar projects in Clinical trials in India, 2 biosimilar projects in Clinical trials in US and Europe, and the rest in early development. • Propelled the commissioning of 1 R&D and 2 cGMP Capital project for Bio-therapeutics research and manufacturing, budget size 25 million + USD.

• Signed 12 + deals amounting 100 million+ USD in revenue - out-licensing, supply agreement, CDMO/CMO deals in India, Brazil, South Korea, LATAM, Russia, Turkey, Pan- Europe, Australia, and USA. • Established the CMO/CDMO business for NBE’s (first-in-class) development and Similar Biologics with a definitive revenue of 50 million+ USD. • Championed various deal models, agreements and 50 + term sheets for a win-win deal making. • Led sales forecasting, Deal & Asset valuation, market trend analysis and segment strategies. • Extensively involved in 10-year business plan for the company. • Negotiated various significant cost improvement programs (CIP) with 3rd party contract manufacturer realized savings of 3-5 million USD. • Developed dashboard metrics to measure and ensure performance, reliability & directed the creation and implementation of a business continuity plan.

• Established from scratch the Business Development, Strategy and Licensing function at Enzene Biosciences and successfully added a wide network of 500+ companies for out- licensing of various Biosimilars (Microbial and CHO) and Synthetic Peptides. • Spearheading the business development initiatives for a portfolio of 10+ Biosimilars, 4+ Synthetic Peptides, 2+ NCE’s in domestic and international markets. • Sourced contract manufacturers, CRO and negotiated the costs that yielded 2-3 million USD annual savings. • Negotiated 20+ prices, terms of sales and service agreements. • Championed smooth Inter-department coordination with Marketing, Manufacturing, Logistics, Regulatory, Finance & Accounts function for smooth transaction planning with potential clients. • Prepared and maintained various documents and records related with Sales, Commissions &Samples (MIS, Order Sheets, Proforma Invoice etc.) to enable smooth transaction execution with potential clients.

• Led the microbial fermentation group and championed the process development of 4+ high value Biosimilar molecules. • Early and Late-stage upstream process development for fusion proteins, monoclonal antibodies and peptibody for Domestic, US and EU markets. • Managed the Design of experiment (DOE) to study the effect of multiple variables on fermentation performance and the effects of interactions between variables through AMBR250 powered by Umetrics MODDE Design of Experiment (DoE) application. • Overlooked 25+ experiments for validation of small scale-model for conducting process characterization studies. • Authored 10+ technical reports, batch records, BPCRs, SOPs, development reports and process protocols for Process development and tech transfer activities. • Successfully presented end-to-end pre-clinical product development data and strategy in RCGM and DCGI meetings for ongoing Biosimilar programs. • Led a project team of 10+ scientists from various R&D departments (upstream, downstream,analytical) as a Technical Project Manager, propelling a mAb program from pre-clinical to Clinical Trial Application (CTA).